# PCC1 and the “150-year pill”: sources and methods Reviewed September 23, 2026 for Managing Expectations / Health / Longevity. This is a bounded evidence review, not a systematic review or medical advice. ## Supplied video - Original: https://vt.tiktok.com/ZSbepP3Uo/ - Canonical: https://www.tiktok.com/@shannanegens/video/7688418368096947486 - Account: shannanegens; metadata upload date September 22, 2026. - Runtime: 105.066667 seconds, confirmed with ffprobe. The complete HEVC/AAC clip was downloaded; a timed-out transfer was resumed using saved metadata. Automatic speech transcription and sampled frames were reviewed. The on-screen paper title identifies the 2021 Nature Metabolism study. Automatic spellings “Lanvi” and “Presyanidin” were corrected to Lonvi and procyanidin C1 using displayed text and primary sources. The creator explicitly acknowledges that the human 150-year claim is unsubstantiated and initially describes the mouse figure as median remaining lifespan. The article preserves those qualifications. The claim that research has not reached humans is too broad given the retrieved human material. Full media, signed CDN URLs and the raw transcript remain private. The public article links the original TikTok with a source-context frame; it does not claim in-page playback or rehost the complete clip. ## Original paper and editorial warning Xu Q, Fu Q, Li Z, et al. *The flavonoid procyanidin C1 has senotherapeutic activity and increases lifespan in mice.* Nature Metabolism 3, 1706–1726 (2021), published December 6, 2021. DOI: 10.1038/s42255-021-00491-8. PMID: 34873338; PMCID: PMC8688144. https://www.nature.com/articles/s42255-021-00491-8 The natural-aging survival experiment used C57BL/6J mice, both sexes, aged 24–27 months: 91 PCC1-treated mice and 80 vehicle controls. The reported increases were 64.2% in median post-treatment lifespan and 9.4% in overall lifespan. The survival cohort received oral gavage; the nearby physical-function experiment using younger male mice and injections is a different experiment. No animal dose was converted into a human recommendation. Percentages are the authors’ reported results, not independently recomputed raw-data estimates. The paper disclosed commercial research funding, patents and company interests, including By-Health support. These disclosures are not evidence of fraud and do not make the study a Lonvi clinical trial. An Editorial Expression of Concern was published February 23, 2026, DOI: 10.1038/s42255-026-01487-y. Publisher text and Crossref update metadata were checked. https://www.nature.com/articles/s42255-026-01487-y The notice concerns the CTRL Vehicle mouse image in Figure 6b, apparently similar to a mouse image in a 2018 paper. The authors requested a correction but could not retrieve the underlying raw data. Do not describe this as a retraction, say all results were disproved, or assert that the notice specifically identifies missing survival-curve data. The relevant lifespan curves are in Figure 8. Both publisher PDFs were downloaded directly, checked for PDF magic bytes, opened and text-extracted: the original is 44 pages; the notice is one page. Both contain Creative Commons licence language and are reproduced unaltered in this package. Always read the original with the notice. ## Human evidence and its limitations ### Company biomarker report The company-affiliated PDF *PCC1 Senolytic Complex Compound’s Preliminary Study on Regulating Cellular Senescence* was downloaded and its methods inspected. Authors include Qun Wang, Jiaxin Liang and Qinghua Lyu. It describes a retrospective, uncontrolled study: 30 volunteers aged 50–86, with 17 included in the final analysis. Inclusion required improving results in at least three of four SASP markers. The report calls this predefined; predefinition does not remove outcome-selection bias. Baseline and day-five blood measurements, PBMC markers and plasma inflammatory markers do not establish body-wide senolysis, longer life or clinical benefit. No adverse events in this small, short study is not proof of long-term safety. The company’s branded shop labels the pilot not peer reviewed; a peer-reviewed publication of this series was not verified. The full company PDF is retained privately; the article links it without reproducing a regimen. ### Registered skin study https://clinicaltrials.gov/study/NCT06641869 https://clinicaltrials.gov/api/v2/studies/NCT06641869 “Study of PCC1 for Skin Rejuvenation” lists Express Rx, Inc as sponsor, not Lonvi. The retrieved record reports completion, actual enrollment of 74, a randomized parallel open-label design and 12-week skin-barrier, wrinkle, texture and radiance outcomes. The last update was posted August 11, 2025. First posting on October 15, 2024 was after the stated August 10, 2024 completion. The API returned `hasResults: false` on September 23, 2026. This means no registry-posted results, not no results anywhere. The main editor independently checked the API fields. PCC1/procyanidin C1 searches returned the same study; the Lonvi query returned no matching record. This was not a comprehensive search of WHO ICTRP, Chinese-language registries or all aliases. No human-lifespan endpoint was identified in the retrieved record. ## Company reporting and subsequent animal work Andrew Higgins’s New York Times report was dated November 8, 2025 in English; the November 10 bilingual edition was retrieved. It attributes a 150-year forecast to CTO Lyu Qinghua, while separately describing a company belief in 100–120 years with healthy living and medical care. It says Lonvi opened its laboratory in 2022 and was not connected to the Shanghai discovery team. Proposed Buck Institute trials mentioned in that reporting were not verified here as completed trials. The publisher corrected an affiliation error: Buck is independent, not part of Stanford. https://cn.nytimes.com/china/20251110/china-aging-longevity-science/zh-hant/dual/ The 2024 PNAS retina paper was checked at abstract level. The 2025 npj Aging paper was read in full and explicitly says lifespan was not assessed. No independent replication of the specific 64.2% survival endpoint was verified in this bounded review. This is not a claim that no follow-up research exists. https://doi.org/10.1073/pnas.2311028121 https://www.nature.com/articles/s41514-025-00222-3 ## Safety boundaries NCCIH’s description of generally tolerated grape-seed extract does not certify every purified PCC1 or enhanced-absorption product. MSK notes possible blood-thinner risks and laboratory interaction findings with uncertain clinical relevance. Health Canada’s assessment applies to specified standardized extracts in supplemented foods and expressly excludes modified forms or special carriers that alter bioavailability and related handling. No product-specific Canadian NPN or approval status was determined. The article offers no dosing schedule, purchase recommendation, medication change or treatment promise. All safety-source URLs are in `source-urls.txt` and linked in the article. ## Publication scope Fresh live Health, Blog and search entries showed no PCC1/Lonvi article or exact TikTok match. This is a distinct source-check linked to existing longevity coverage. Scope is ManagingExpectations.net only—not .com, PBC or My Cancer PDF. Deployment is limited to the manifest, with backups and shared-file change detection. Health, Blog, homepage, search and sitemap are updated. No existing root RSS/Atom file was found; no feed update is claimed.